It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Emerging evidence is revealing that alterations in gut microbiota are associated with colorectal cancer (CRC). However, very little is currently known about whether and how gut microbiota alterations are causally associated with CRC development. Here we show that 12 faecal bacterial taxa are enriched in CRC patients in two independent cohort studies. Among them, 2 Porphyromonas species are capable of inducing cellular senescence, an oncogenic stress response, through the secretion of the bacterial metabolite, butyrate. Notably, the invasion of these bacteria is observed in the CRC tissues, coinciding with the elevation of butyrate levels and signs of senescence-associated inflammatory phenotypes. Moreover, although the administration of these bacteria into ApcΔ14/+ mice accelerate the onset of colorectal tumours, this is not the case when bacterial butyrate-synthesis genes are disrupted. These results suggest a causal relationship between Porphyromonas species overgrowth and colorectal tumourigenesis which may be due to butyrate-induced senescence.
Several bacteria in the gut microbiota have been associated with colorectal cancer (CRC) but it is not completely clear whether they have a role in tumourigenesis. Here, the authors show enrichment of 12 bacterial taxa in two cohorts of CRC patients and that two Porphyromonas species accelerate CRC onset through butyrate secretion.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Konishi Yusuke 2 ; Narukawa Megumi 2 ; Sugiura Yuki 3 ; Yoshimoto Shin 4 ; Arai Yuriko 5 ; Sato Shintaro 2 ; Yoshida Yasuo 6 ; Tsuji Shunya 2 ; Uemura, Ken 2 ; Wakita Masahiro 7 ; Matsudaira Tatsuyuki 2 ; Matsumoto Tomonori 2 ; Kawamoto Shimpei 2 ; Takahashi, Akiko 5
; Itatani Yoshiro 8
; Miki Hiroaki 2
; Takamatsu Manabu 9 ; Obama Kazutaka 8 ; Takeuchi Kengo 10
; Suematsu Makoto 3
; Ohtani Naoko 11
; Fukunaga Yosuke 9
; Ueno Masashi 9 ; Sakai Yoshiharu 8 ; Nagayama Satoshi 9
; Hara Eiji 12
1 Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Graduate School of Medicine, Kyoto University, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
2 Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
3 Keio University School of Medicine, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
4 The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); LSI Medience Corporation, Tokyo, Japan (GRID:grid.410807.a)
5 The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131)
6 School of Dentistry, Aichi Gakuin University, Nagoya, Japan (GRID:grid.411253.0) (ISNI:0000 0001 2189 9594)
7 Immunology Frontier Research Centre (IFReC), Osaka University, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
8 Graduate School of Medicine, Kyoto University, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
9 The Cancer Institute Hospital, JFCR, Tokyo, Japan (GRID:grid.486756.e) (ISNI:0000 0004 0443 165X)
10 The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); The Cancer Institute Hospital, JFCR, Tokyo, Japan (GRID:grid.486756.e) (ISNI:0000 0004 0443 165X)
11 Osaka City University Graduate School of Medicine, Osaka, Japan (GRID:grid.261445.0) (ISNI:0000 0001 1009 6411)
12 Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Immunology Frontier Research Centre (IFReC), Osaka University, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)




